Systemic dysregulation of CEACAM1 in melanoma patients

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 215-230

  Markel, Gal ^a,b   Ortenberg, Rona ^a,b   Seidman, Rachel ^a   Sapoznik, Sivan ^a   Koren Morag, Nira ^b   Besser, Michal J ^a   Bar, Jair ^a   Shapira, Ronnie ^a   Kubi, Adva ^a   Nardini, Gil ^a   Tessone, Ariel ^a   Treves, Avraham J ^a   Winkler, Eyal ^a   Orenstein, Arie ^a   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biomarker; CEACAM1; Inhibition; Lymphocytes; Melanoma; Serum

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SERUM; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; CELL ADHESION MOLECULES; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; RECEPTORS, IGG; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 71849114335     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0740-5     Document Type: Article

References (46)

1. National Cancer Institute. Surveillance epidemiology and end results. http://seer.cancer.gov/csr/1975-2004/results-merged/sect-16-melanoma.pdf. Last accessed at 28 January 2009
2. National Cancer Institute. Surveillance epidemiology and end results. http://seer.cancer.gov/publications/aya/5-melanoma.pdf. Last accessed at 28 January 2009
3. M Herlyn 1990 Human melanoma: development and progression Cancer Metastasis Rev 9 101 112 10.1007/BF00046337 1:STN:280:DyaK3M%2FntVKqtg%3D%3D 2253310
4. A Breslow 1970 Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg 172 902 908 10.1097/00000658- 197011000-00017 1:STN:280:DyaE3M%2FivVOgtw%3D%3D 5477666
5. S-J Soong HM Shaw CM Balch, et al. 1992 Predicting survival and recurrence in localized melanoma: a multivariate approach World J Surg 16 191 195 10.1007/BF02071520 1:STN:280:DyaK383itFKnsQ%3D%3D 1561798
6. L Schuchter DJ Schultz M Synnestvedt, et al. 1996 A prognostic model for predicting 10-year survival in patients with primary melanoma Ann Intern Med 125 369 375 1:STN:280:DyaK28zjt1WgsA%3D%3D 8702087
7. DF Christianson CM Anderson 2003 Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma Semin Oncol 30 369 374 10.1016/S0093-7754(03)00097-6 12870138 (Pubitemid 36706561)
8. C Garbe A Paul H Kohler-Späth, et al. 2003 Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy J Clin Oncol 21 520 529 10.1200/JCO.2003.01.091 12560444 (Pubitemid 46606483)
9. M Deichmann A Benner M Bock, et al. 1999 S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma J Clin Oncol 17 1891 1896 1:STN:280:DC%2BD3c%2FivF2muw%3D%3D 10561230
10. M Deichmann B Kahle K Moser, et al. 2004 Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase Br J Cancer 91 699 702 1:CAS:528:DC%2BD2cXmsVCgtro%3D 15280926
11. N Beauchemin P Draber G Dveksler, et al. 1999 Redefined nomenclature for members of the carcinoembryonic antigen family Exp Cell Res 252 243 249 10.1006/excr.1999.4610 1:STN:280:DC%2BD3Mvls1Kjsg%3D%3D 11501563 (Pubitemid 29530255)
12. NJ Vogelzang PH Lange A Goldman 1982 Acute changes of α-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors Cancer Res 42 4855 4861 1:STN:280:DyaL3s%2FisVyjsQ%3D%3D 6181870
13. GY Locker S Hamilton J Harris, et al. 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 5313 5327 10.1200/JCO.2006.08.2644 1:CAS:528:DC%2BD28XhtlemurfN 17060676 (Pubitemid 46631379)
14. S Hammarström 1999 The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 67 81 10.1006/scbi.1998.0119 10202129 (Pubitemid 29265523)
15. A Thies I Moll J Berger, et al. 2002 CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease J Clin Oncol 20 2530 2536 10.1200/JCO.2002.05.033 1:CAS:528:DC%2BD38XksFakurY%3D 12011132 (Pubitemid 34525740)
16. E Laack H Nikbakht A Peters, et al. 2002 Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance J Clin Oncol 20 4279 4284 10.1200/JCO.2002.08.067 12409325 (Pubitemid 35266287)
17. W Sienel S Dango U Woelfle, et al. 2003 Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer Clin Cancer Res 9 2260 2266 1:CAS:528: DC%2BD3sXksVajsro%3D 12796394
18. A Ebrahimnejad T Streichert P Nollau, et al. 2004 CEACAM1 enhances invasion and migration of melanocytic and melanoma cells Am J Pathol 165 1781 1787 1:CAS:528:DC%2BD2cXhtVCgsbrO 15509546
19. G Markel D Wolf J Hanna, et al. 2002 Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions J Clin Invest 110 943 953 1:CAS:528:DC%2BD38XnslSksbs%3D 12370272
20. G Markel N Lieberman G Katz, et al. 2002 CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity J Immunol 168 2803 2810 1:CAS:528:DC%2BD38XitFSkt7c%3D 11884449
21. G Markel R Seidman N Stern, et al. 2006 Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions J Immunol 177 6062 6071 1:CAS:528:DC%2BD28XhtFSns73N 17056532
22. Markel G, Seidman R, Cohen Y et al. (2008) Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology [Epub ahead of print]
23. L Dráberová H Cerná H Brodská, et al. 2000 Soluble isoforms of CEACAM1 containing the A2 domain: increased serum levels in patients with obstructive jaundice and differences in 3-fucosyl-N-acetyl- lactosamine moiety Immunology 101 279 287 10.1046/j.1365-2567.2000.00113.x 11012782 (Pubitemid 30765988)
24. Y Kondo Y Hinoda H Akashi, et al. 2001 Measurement of circulating biliary glycoprotein (CD66a) in liver diseases J Gastroenterol 36 470 475 10.1007/s005350170070 1:STN:280:DC%2BD38%2Fis1Clsw%3D%3D 11480791 (Pubitemid 32747207)
25. T Svenberg B Wahren S Hammarström 1979 Elevated serum levels of a biliary glycoprotein (BGP I) in patients with liver or biliary tract disease Clin Exp Immunol 36 317 325 1:STN:280:DyaL3c%2Fgt1emsw%3D%3D 477033
26. DM Simeone B Ji M Banerjee, et al. 2007 CEACAM1, a novel serum biomarker for pancreatic cancer Pancreas 34 436 443 10.1097/MPA.0b013e3180333ae3 1:CAS:528:DC%2BD2sXls1Gltb0%3D 17446843 (Pubitemid 46725785)
27. MJ Moller R Kammerer F Grunert, et al. 1996 Biliary glycoprotein (BGP) expression on T cells and on a natural-killer-cell sub-population Int J Cancer 65 740 745 10.1002/(SICI)1097-0215(19960315)65:6<740::AID-IJC5>3.0.CO;2-Z 1:STN:280:DyaK283gtVamtw%3D%3D 8631584 (Pubitemid 26127751)
28. R Kammerer S Hahn BB Singer, et al. 1998 Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation Eur J Immunol 28 3664 3674 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D 1:CAS:528:DyaK1cXnsFKjsrk%3D 9842909 (Pubitemid 28510777)
29. B Albarran-Somoza R Franco-Topete V Delgado-Rizo, et al. 2006 CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection J Histochem Cytochem 54 1393 1399 10.1369/jhc.6A6921.2006 1:CAS:528:DC%2BD28Xht1CnurvJ 16924126 (Pubitemid 44788824)
30. G Markel R Gruda H Achdout, et al. 2004 The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells J Immunol 173 3732 3739 1:CAS:528: DC%2BD2cXnsVWltb0%3D 15356119
31. T Takino H Saeki H Miyamori, et al. 2007 Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions Cancer Res 67 11621 11629 10.1158/0008-5472.CAN-07-5251 1:CAS:528:DC%2BD2sXhsVCjs7rJ 18089791
32. G Markel H Achdout G Katz, et al. 2004 Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients Eur J Immunol 34 2138 2148 10.1002/eji.200425021 1:CAS:528:DC%2BD2cXmslanuro%3D 15259011 (Pubitemid 39256095)
33. V Groh J Wu C Yee, et al. 2002 Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 734 738 10.1038/nature01112 1:CAS:528:DC%2BD38XnvVyrt7o%3D 12384702 (Pubitemid 35177960)
34. CS Vetter V Groh P thor Straten, et al. 2002 Expression of stress-induced MHC class I related chain molecules on human melanoma J Invest Dermatol 118 600 605 10.1046/j.1523-1747.2002.01700.x 1:CAS:528:DC%2BD38Xjt1Cju7g%3D 11918705 (Pubitemid 34309978)
35. L Izzi C Turbide C Houde, et al. 1999 cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function Oncogene 18 5563 5572 10.1038/sj.onc.1202935 1:CAS:528:DyaK1MXmvVOrsL0%3D 10523833 (Pubitemid 29481503)
36. AK Horst WD Ito J Dabelstein, et al. 2006 Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo J Clin Invest 116 1596 1605 10.1172/JCI24340 1:CAS:528: DC%2BD28XlsFWrurg%3D 16680193 (Pubitemid 43911013)
37. K Wikström G Kjellström B Obrink 1996 Homophilic intercellular adhesion mediated by C-CAM is due to a domain 1-domain 1 reciprocal binding Exp Cell Res 227 360 366 10.1006/excr.1996.0285 8831574 (Pubitemid 26320178)
38. A Thies S Mauer O Fodstad, et al. 2007 Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice Br J Cancer 96 609 616 10.1038/sj.bjc.6603594 1:CAS:528: DC%2BD2sXhvV2jtrk%3D 17262079 (Pubitemid 46303536)
39. SD Gray-Owen RS Blumberg 2006 CEACAM1: contact-dependent control of immunity Nat Rev Immunol 6 433 446 10.1038/nri1864 1:CAS:528: DC%2BD28XkvVyrt78%3D 16724098
40. TR Barnett L Drake W Pickle II 1993 Human biliary glycoprotein gene: characterization of a family of novel alternatively spliced RNAs and their expressed proteins Mol Cell Biol 13 1273 1282 1:CAS:528:DyaK2cXpslCltg%3D%3D 8423792
41. M Budt B Michely MM Müller 2002 Secreted CEACAM1 splice variants in rat cell lines and in vivo in rat serum Biochem Biophys Res Commun 292 749 755 10.1006/bbrc.2002.6704 1:CAS:528:DC%2BD38XitlGmsro%3D 11922629 (Pubitemid 34681122)
42. TA Stamey N Yang AR Hay, et al. 1987 Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 909 916 1:STN:280:DyaL2szhsFakug%3D%3D 2442609
43. N Azuz-Lieberman G Markel S Mizrahi, et al. 2005 Involvement Natural Killer cells and CEACAM1 in Ankylosing Spondylitis Int Immunol 17 837 845 10.1093/intimm/dxh270 1:CAS:528:DC%2BD2MXmt1eku7Y%3D 15937057 (Pubitemid 41417951)
44. G Markel H Mussaffi KL Ling, et al. 2004 The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients Blood 10 31770 31778
45. H Takahashi Y Okai RJ Paxton, et al. 1993 Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon Cancer Res 53 1612 1619 1:CAS:528:DyaK3sXitlajsr0%3D 8453631
46. G Konjević K Mirjacić Martinović A Vuletić, et al. 2007 Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients Clin Exp Metastasis 24 1 11 10.1007/s10585-006-9043-9 17295095 (Pubitemid 46569334)